Current management of heart failure

Practitioner

Volumn 246, Issue 1635, 2002, Pages 438-441

  Fisher, Carol ^a   McMurray, John J V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIOCARDIOGRAPHY; BIOPSY; BLOOD; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; HUMAN; HYPERTENSION; METHODOLOGY; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; BIOPSY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION;

EID: 0036598785     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Caruana L et al. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from 'diastolic heart failure' or from misdiagnosis? A prospective descriptive study. BMJ 2000;321(7255):215-218
2. Cowie MR et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J 1999;20(6):421-428
3. Love MP et al. Endothelin in heart failure: a promising therapeutic target? Heart 1997;77(2):93-94
4. McDonagh TA et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351(9095):9-13
5. Stewart S et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3(3):315-322
6. Davie AP et al. Assessing diagnosis in heart failure: which features are any use? QJM 1997;90(5):335-339
7. Flather MD et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355(9215):1575-1581
8. CONSENSUS Study Group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435
9. The Study of Left Ventricular Dysfunction (SOLVD) Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
10. Cleland J et al. The evidence for β-blockers in heart failure. BMJ 1999;318:824-825
11. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
12. Hjalmarson A et al. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007
13. Packer M. Results of COPERNICUS Trial presented at the XXII Congress of the European Society of Cardiology Amsterdam August 2000
14. McMurray JJV et al. Practical recommendations for the use of ACE inhibitors, β-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Failure 2001;3(4):495-502
15. Pitt B et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
16. Berry C et al. Serious adverse events experienced by patients with chronic heart failure. Heart 2001;85(4):E8
17. Schepkens H et al. Life-threatening hyperkalaemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110(6):438-441
18. Perry G et al. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533
19. Remme WJ et al. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22(17):1527-1560